Robert F. Williamson III Buys 38,145 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) Stock

Perspective Therapeutics, Inc. (NYSE:CATX) Director Robert F. Williamson III bought 38,145 shares of Perspective Therapeutics stock in a transaction on Monday, March 31st. The shares were bought at an average cost of $2.14 per share, with a total value of $81,630.30. Following the acquisition, the director now directly owns 108,982 shares in the company, valued at approximately $233,221.48. This represents a 53.85 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Perspective Therapeutics Price Performance

Shares of NYSE CATX opened at $2.05 on Thursday. The stock’s 50-day moving average is $2.85 and its 200 day moving average is $6.07. Perspective Therapeutics, Inc. has a 1-year low of $1.90 and a 1-year high of $19.05.

Analysts Set New Price Targets

A number of research firms recently weighed in on CATX. Brookline Capital Management raised shares of Perspective Therapeutics to a “strong-buy” rating in a report on Monday, March 10th. Lifesci Capital upgraded Perspective Therapeutics to a “strong-buy” rating in a research report on Thursday, March 6th. Royal Bank of Canada dropped their price objective on Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating for the company in a research note on Thursday, March 27th. Scotiabank initiated coverage on Perspective Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 target price on the stock. Finally, Wedbush reiterated an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a research report on Wednesday, March 26th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $14.44.

Institutional Investors Weigh In On Perspective Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Intech Investment Management LLC purchased a new position in Perspective Therapeutics in the 3rd quarter worth $137,000. Charles Schwab Investment Management Inc. increased its holdings in shares of Perspective Therapeutics by 221.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company’s stock worth $5,788,000 after buying an additional 298,778 shares during the period. The Manufacturers Life Insurance Company lifted its stake in shares of Perspective Therapeutics by 8.9% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 20,514 shares of the company’s stock valued at $274,000 after acquiring an additional 1,672 shares during the last quarter. FMR LLC boosted its holdings in Perspective Therapeutics by 3,994.9% during the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company’s stock valued at $73,489,000 after acquiring an additional 5,370,392 shares during the period. Finally, BNP Paribas Financial Markets grew its position in Perspective Therapeutics by 1,302.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 47,565 shares of the company’s stock worth $635,000 after acquiring an additional 44,174 shares during the last quarter. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.